Intellia Therapeutics Files 8-K
Ticker: NTLA · Form: 8-K · Filed: Jan 10, 2025 · CIK: 1652130
Sentiment: neutral
Topics: corporate-events, disclosure
TL;DR
Intellia Therapeutics filed an 8-K on Jan 9th covering operations, exits, and exec changes.
AI Summary
Intellia Therapeutics, Inc. filed an 8-K on January 10, 2025, reporting on events as of January 9, 2025. The filing covers results of operations, costs associated with exit or disposal activities, changes in directors or officers, and includes Regulation FD disclosures and financial statements. Specific financial figures or operational details were not provided in this excerpt.
Why It Matters
This 8-K filing indicates significant corporate events are being disclosed by Intellia Therapeutics, potentially impacting investors' understanding of the company's operational status and strategic direction.
Risk Assessment
Risk Level: medium — 8-K filings often contain material information that can significantly impact a company's stock price, necessitating careful review by investors.
Key Players & Entities
- Intellia Therapeutics, Inc. (company) — Registrant
- January 9, 2025 (date) — Date of earliest event reported
- January 10, 2025 (date) — Date of Report
FAQ
What specific results of operations are being reported by Intellia Therapeutics?
The filing indicates that results of operations are being reported, but the specific details are not provided in this excerpt.
Are there any costs associated with exit or disposal activities mentioned in the filing?
Yes, the filing lists 'Cost Associated with Exit or Disposal Activities' as an item being reported.
What changes in company personnel are being disclosed?
The filing covers 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers' and 'Compensatory Arrangements of Certain Officers'.
Does the filing include any Regulation FD disclosures?
Yes, 'Regulation FD Disclosure' is listed as an item covered in the 8-K.
What is the exact date of the earliest event reported in this 8-K?
The earliest event reported is dated January 9, 2025.
Filing Stats: 2,832 words · 11 min read · ~9 pages · Grade level 15 · Accepted 2025-01-10 07:30:22
Key Financial Figures
- $0.0001 — ich registered Common Stock (Par Value $0.0001) NTLA The Nasdaq Global Market Ind
- $862 million — cts to report that it had approximately $862 million of cash, cash equivalents and marketabl
- $8 million — it will incur charges of approximately $8 million for severance and other employee termin
- $384,000 — o will receive a revised base salary of $384,000 during the remainder of her employment
Filing Documents
- d906527d8k.htm (8-K) — 60KB
- d906527dex991.htm (EX-99.1) — 36KB
- g906527g0110034504806.jpg (GRAPHIC) — 7KB
- 0001193125-25-004080.txt ( ) — 241KB
- ntla-20250109.xsd (EX-101.SCH) — 3KB
- ntla-20250109_lab.xml (EX-101.LAB) — 18KB
- ntla-20250109_pre.xml (EX-101.PRE) — 11KB
- d906527d8k_htm.xml (XML) — 4KB
Forward Looking Statements
Forward Looking Statements. This Current Report on Form 8-K and certain of the materials furnished or filed herewith contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding the Company's beliefs and expectations regarding: ability to successfully develop and commercialize nexiguran ziclumeran ("nex-z"), formerly known as NTLA-2001, for the treatment of transthyretin ("ATTR") amyloidosis and NTLA-2002 for the treatment of hereditary angioedema ("HAE") to address the significant unmet needs of patients and prescribers in HAE and ATTR; its ability to achieve near-term clinical milestones, including dosing the first patient in the Phase 3 HAELO trial in the first quarter of 2025, completing enrollment in the Phase 3 HAELO trial in the second half of 2025, dosing the first patient in the Phase 3 MAGNITUDE-2 trial for hereditary ATTR with polyneuropathy ("ATTRv-PN") in the first quarter of 2025, enroll at least 550 patients across the Phase 3 MAGNITUDE trial for ATTR with cardiomyopathy ("ATTR-CM") by year-end, and the expected timing of data releases from its clinical trials of nex-z and NTLA-2002, including longer-term data from the Phase 1/2 study of NTLA-2002, including data from patients that previously received the 25 mg dose or placebo and were subsequently given the 50 mg dose, and longer-term data from the Phase 1 study of nex-z, including updated measure of clinical efficacy and safety; its ability to prepare for commercial launch, including completing buildout of th
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Intellia Therapeutics, Inc. Date: January 10, 2025 By: /s/ John M. Leonard Name: John M. Leonard Title: Chief Executive Officer and President